Travoprost/Brinzolamide Fixed Combination Versus Travatan and Versus AZOPT

Inclusion Criteria:

• 18 YOA or older

• Either gender or any race

• OAG or OHT

• Currently on stable (at least 4 weeks) IOP lowering medication

• IOP at screening visit ≥ 18mmHg in at least one eye

• Mean IOP in same eye (at both eligibility 1&2 visits

• 24 and 36 mmHg at 9AM

• 21 and 36 mmHg at 11AM and 4PM

• Able to discontinue use of IOP lowering medication for a minimum wash out period of 5to 28 days prior to eligibility visit 1

Exclusion Criteria: Related to disease condition being investigated (OAG or OHT) in either eye

• Severe central visual field loss

• Angle shaffer grade < 2

• C/D ratio >0.8(horizontal or vertical measurement) Related to ocular patient history or current ocular condition in either eye

• BSCVA worse than 55 ETDRS letters read (equivalent to approximately 20/80 Snellen or 0.25 decimal)

• Ocular infection or inflammation or laser surgery within the last 3 months

• Intraocular surgery or trauma with the last 6 months

• Any abnormality preventing reliable applanation tonometry

• History or chronic, recurrently or current severe inflammatory disease

• History of or current clinically significant or progressive retinal disease

• History of or current ocular pathology(including severe dry eye) that would affect theconduct of the study Related to systemic or ocular medication in either eye

• Allergy/hypersensitivity to study medications

• Unable to discontinue glucocorticoid at least 4 weeks prior to the study or unable toremain off these medications during the study period

• Use of oral CAIs during the study

• Recent use (<4 weeks prior to the study) of Aspirin (>1 gram)

• Less than 30 days stable dosing regimen of medications used on a chronic basis thatmay affect IOP

• Therapy with another investigational agent within 30 days prior to the Screening Visit